In an exploratory analysis in patients with advanced breast cancer treated with durvalumab, HR for ICI efficacy with CD274 gain/amplification was 0.18 (95%CI = 0.05–0.71, p = 0.0059), with CD274 normal/loss ICI efficacy HR = 1.12 (95%CI = 0.42–2.99, p = 0.8139) [35]. Here, CD274 is linked to breast carcinoma.